Ivona Mazarianu

Mrs. Ivona Mazarianu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
IMIvona Mazarianu
Ivona Mazarianu
Gabriela-Dumitrita StanciuGabriela-Dumitrita Stanciu
Gabriela-Dumitrita Stanciu
GRGogu Maria Raluca
Gogu Maria Raluca
BTBogdan Tamba
Bogdan Tamba
Alzheimer’s disease (AD) is primarily recognized for progressive cognitive decline driven by beta-amyloid accumulation and tau pathology. However, many individuals with AD also experience chronic pain and depressive symptoms, which significantly impair daily functioning and quality of life and increase caregiver burden. These non-cognitive features are frequently underrecognized, despite evidence suggesting they share overlapping biological pathways with neurodegeneration. Emerging data highlight the role of neuroinflammation, oxidative stress, hypothalamic–pituitary–adrenal axis dysregulation, and endocannabinoid system alterations in linking AD pathology to disturbances in pain processing and mood regulation. Persistent microglial activation, cytokine imbalance, redox disruption, and chronic stress signaling may simultaneously promote neuronal vulnerability while shaping affective and nociceptive responses. This review synthesizes current preclinical and clinical evidence on the interplay between pain, depression, and AD, emphasizing their shared pathophysiological mechanisms and clinical relevance. Recognizing these symptoms as integral components of disease progression, rather than isolated comorbidities, can inform the development of integrated, multidimensional therapeutic strategies in AD care.

19 March 2026 in Life
Verified
Journal Article
Open access
PDF file
Gabriela-Dumitrita StanciuGabriela-Dumitrita Stanciu
Gabriela-Dumitrita Stanciu
IMIvona Mazarianu
Ivona Mazarianu
DCDascalu Camelia
Dascalu Camelia
BTBogdan Tamba
Bogdan Tamba
Alzheimer’s disease (AD) remains a major unmet medical challenge due to its complex pathology, high interpatient heterogeneity and frequent association with systemic comorbidities. Conventional pharmacotherapy is limited by poor blood–brain barrier permeability, off-target effects and reduced efficacy in polymedicated elderly populations. Smart drug-delivery systems (DDS), particularly nanotechnology-based platforms, have emerged as promising strategies to enhance brain targeting, optimize controlled drug release and mitigate systemic toxicity. This review examines recent advances in intelligent DDS for AD, with a focus on nanocarriers designed to modulate amyloid aggregation, neuroinflammation, oxidative stress and cholinergic dysfunction. Special attention is given to the impact of the most common comorbid conditions on DDS pharmacokinetics, safety and clinical performance. Furthermore, the challenges associated with clinical translation, such as long-term safety, immunogenicity, manufacturing scalability and regulatory harmonization, are critically discussed. In this context, versatile controlled release platforms that integrate rational design, predictive modeling and Quality by Design-driven manufacturing are highlighted as key enablers of translational success. By bridging intelligent formulation design with scalable production and regulatory readiness, advanced controlled release systems offer a pathway toward precision and patient-centered therapies. Such platforms hold significant potential to accelerate the safe integration of smart DDS into Alzheimer’s disease management and broader neurotherapeutic applications.

24 April 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
Loredana Mariana CurecheriuLoredana Mariana Curecheriu
Loredana Mariana Curecheriu
BIBogdan Florin Iliescu
Bogdan Florin Iliescu
Gabriela-Dumitrita StanciuGabriela-Dumitrita Stanciu
Gabriela-Dumitrita Stanciu
IMIvona Mazarianu
Ivona Mazarianu
Andrei SzilagyiAndrei Szilagyi
Andrei Szilagyi
MTMihaela Dana Turliuc
Mihaela Dana Turliuc
Background: Standardized and ethically compliant animal models remain essential for improving translational research in Alzheimer’s disease. Although Aβ1–42-induced rodent models are widely used, methodological variability continues to limit reproducibility. Methods: We explored the feasibility of a stereotactic intrahippocampal Aβ1–42 rat model established by bilaterally injecting pre-aggregated peptide into the hippocampus of adult Sprague Dawley rats. Model feasibility and targeting accuracy were assessed intraoperatively. Cognitive performance was evaluated using the Y-maze for spatial recognition memory and the novel object recognition (NOR) test. Histological examination was performed using hematoxylin–eosin (H&E) and Congo red staining to assess cytoarchitecture and to provide supportive evidence of amyloid-like deposits. Results: The surgical procedure was well-tolerated, and the injected animals showed reduced performance in behavioural testing, including reduced spatial recognition memory in the Y-maze and decreased discrimination indices in the NOR test. The animals also showed histological changes, including Congo red-positive birefringent structures consistent with amyloid-like congophilic material. Conclusions: This study presents a feasible experimental framework for intrahippocampal Aβ1–42 administration, showing behavioural and histological changes under the present experimental conditions. However, further validation, including sham-operated controls and molecular characterization, will be required before these findings can be interpreted as specific to Aβ-driven pathology.

5 April 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TITeodora Iurascu
Teodora Iurascu
Andreea Teodora IacobAndreea Teodora Iacob
Andreea Teodora Iacob
CSCarmen Solcan
Carmen Solcan
Cristina Mariana UrituCristina Mariana Uritu
Cristina Mariana Uritu
BPBianca Stefania Profire
Bianca Stefania Profire
LPLenuta Profire
Lenuta Profire
Background: Wound healing remains a major clinical challenge, often impaired by persistent inflammation, oxidative stress, and abnormal extracellular matrix remodeling. Electrospun nanofibers (NFs) have emerged as promising wound dressing platforms due to their biomimetic structure and capacity to incorporate multiple bioactive compounds (ACs) with synergistic therapeutic effects. Objectives: This study aimed to biologically assess novel chitosan/poly(vinyl alcohol) (CH/PVA) NFs functionalized with natural active compounds (L-arginine—ARG, allantoin—ALA, royal jelly—RJ, and curcumin—CUR) as multifunctional systems for wound healing and tissue remodeling. Methods: The nanofibrous systems performed the in vitro evaluation of antioxidant activity (DPPH, ABTS, FRAP, PRAP), anti-inflammatory potential (protein denaturation test), hemocompatibility, and cytocompatibility using dermal fibroblasts. In vivo healing performance was evaluated in an excisional wound model using macroscopic wound contraction analysis, histopathology, and immunohistochemical staining (MMP-9, CD31, VEGF-A, α-SMA). Results: The bioactive-enriched CH/PVA NFs exhibited strong antioxidant and anti-inflammatory activity, excellent hemocompatibility (hemolysis < 5%), and excellent cytocompatibility, with promoting fibroblast proliferation. In vivo experiments revealed that the treated groups exhibited accelerated wound closure, improved re-epithelialization, increased angiogenesis, and showed more efficient tissue remodeling compared to the controls, as validated by histological and immunohistochemical studies. Conclusions: The findings indicate that bioactive-enriched CH/PVA NFs serve as effective, biocompatible, and multifunctional matrices for wound healing, hence endorsing their potential for further translational advancement in skin regeneration applications.

9 October 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GRGogu Maria Raluca
Gogu Maria Raluca
IMIvona Mazarianu
Ivona Mazarianu
Gabriela-Dumitrita StanciuGabriela-Dumitrita Stanciu
Gabriela-Dumitrita Stanciu
BTBogdan Tamba
Bogdan Tamba
MCMitica Ciorpac
Mitica Ciorpac
LGLucian Gorgan
Lucian Gorgan
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid (Aβ) deposition, tau pathology and cognitive decline. Increasing evidence from genetic, transcriptomic, experimental and clinical studies has identified microglia as key regulators of AD pathogenesis. Under physiological conditions, microglia maintain central nervous system homeostasis through immune surveillance, phagocytosis and neurotrophic support. However, persistent exposure to pathological stimuli promotes a shift toward dysfunctional inflammatory states that contribute to neuroinflammation, synaptic impairment, tau propagation and neurodegeneration. Recent advances have revealed substantial microglial heterogeneity, highlighting the existence of dynamic and disease stage-dependent activation states rather than fixed phenotypes. In early disease stages, microglia can promote Aβ clearance and tissue repair, whereas chronic activation may exacerbate pathological processes. These findings have driven the development of microglia-targeted therapeutic strategies aimed at enhancing protective functions while limiting maladaptive inflammatory responses. This review summarizes current knowledge regarding microglial involvement in AD and discusses emerging therapeutic approaches, ranging from immunomodulation and metabolic reprogramming to gene-based and nanotechnology-driven interventions, with a focus on their translational potential.

1 May 2026
Verified
Book Chapter
Closed access
FRFlorin Rotaru
Florin Rotaru
Silviu Ioan BejinariuSilviu Ioan Bejinariu
Silviu Ioan Bejinariu
HCHariton Nicolae Costin
Hariton Nicolae Costin
MLMIHAELA LUCA
MIHAELA LUCA
RLRamona Luca
Ramona Luca
Gabriela-Dumitrita StanciuGabriela-Dumitrita Stanciu
Gabriela-Dumitrita Stanciu